Why is argenx stock rallying today?

argenx rose 4.7% to €738.6 after falling about 15.9% on October 8, when its Phase 3 UNITY study of subcutaneous efgartigimod in Sjögren’s disease was halted because it was unlikely to meet its primary endpoint. A successful Phase 2 FB102 celiac-disease study and maintained Buy/Outperform ratings helped support the rebound; Goldman Sachs cut its price target from €982 to €954, while Wedbush lowered its target from $1,150 to $1,130. The stock remains below its 52-week high of €925, with an earnings call scheduled for October 21.

Analysis

The bounce is a flow signal, not evidence that the Sjögren’s failure was economically immaterial. The key distinction is whether this was indication-specific or exposes a broader limitation in subcutaneous efgartigimod’s efficacy, dosing, or patient selection; the interim futility result alone does not resolve that. Near term, analyst reiterations and a separate celiac readout can cushion sentiment, but price recovery driven by target changes risks overstating what those targets independently validate. Over 1–3 months, the October 21 call matters less for broad pipeline optimism than for management’s account of the failed trial, remaining development spend, and whether resources shift to better-supported programs. Over 6–18 months, repeated readouts will determine whether investors continue to value argenx as a multi-indication platform or apply a higher discount to pipeline probability. The contrarian point: the selloff may have overshot the loss of one indication, yet the rebound may be underpricing the information value of a Phase 3 futility stop. FB102’s Phase 2 endpoint success is not yet a substitute for full efficacy, safety, and durability data. A platform-wide efficacy concern or weak subsequent data would falsify the recovery thesis; detailed evidence that the failure is confined to Sjögren’s, alongside credible capital reallocation, would weaken the bearish case.

Key Decisions for Investors

• Avoid chasing the rebound. Treat ARGX as event-driven until the October 21 call and full trial disclosures clarify whether the failure was indication-specific; analyst target maintenance is not a clinical catalyst.
• Tactical idea: consider a small, defined-risk bearish position only if ARGX gives back the recovery and renewed weakness is accompanied by deterioration in management guidance or pipeline commentary. Reassess or cover if management convincingly isolates the failure and preserves confidence in other efgartigimod indications.
• For a 1–3 month watch, verify the UNITY futility details, including endpoint trend, exposure/dosing, and safety, plus the full FB102 dataset. Do not treat a primary-endpoint hit alone as proof of commercial potential.
• Do not infer a direct trade in AB or GS from the analyst actions cited; the article provides no material earnings or exposure mechanism for either mapped company.